Literature DB >> 28941301

Cystatin C predicts acute kidney injury and mortality in cirrhotics: A prospective cohort study.

Rakhi Maiwall1, Awinash Kumar1, Ankit Bhardwaj2, Guresh Kumar2, Ajeet S Bhadoria2, Shiv K Sarin1.   

Abstract

BACKGROUND & AIMS: Acute kidney injury is a frequent and ominous complication in cirrhosis. An episode of AKI damages the functional nephron mass, compromising the renal functional reserve. We aimed to study the incidence of AKI, probability of subsequent episodes, whether AKI itself predisposes to future AKI and the reliability of serum cystatin C(sCyC) as a biomarker in a prospective cohort of cirrhotics. PATIENTS AND METHODS: Five hundred and thirty-one cirrhotics without ongoing AKI were followed for development/resolution of AKI. Predictive models for AKI and mortality were developed and validated (Gr. A, Derivative cohort [n = 273], Gr. B, Validation Cohort [n = 258]).
RESULTS: 365 episodes of AKI occurred in 233 patients; yielding a mean of 1.56 episodes of AKI per patient. In Gr. A and B, 97 (35.5%) and 78 (30%) patients had prior AKI episodes and were predisposed to further attacks (Gr. A, HR 3.9, 95% CI 2.7-5.6, Gr. B, HR 3.6, 95% CI 2.5-5.4). AKI was thus an independent predictor of the development of new AKI(P < .05) and this risk increased significantly with increase in the number of AKI episodes (P < .001). S.CysC but not s.Cr was an independent predictor of new AKI on multivariate analysis. "AKI-Score" incorporating CysC; and the addition of Cyst into components of MELD, that is the "MELD-Cystatin" score predicted the development of AKI and mortality, respectively, and performed significantly better than the MELD and CTP scores.
CONCLUSIONS: An episode of AKI itself predisposes to subsequent attacks of AKI in cirrhotics. Scores incorporating CysC can accurately predict the development of AKI and mortality in these patients.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  acute kidney injury; biomarker; cirrhosis; cystatin C; hepatorenal syndrome; portal hypertension

Mesh:

Substances:

Year:  2017        PMID: 28941301     DOI: 10.1111/liv.13600

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  16 in total

1.  Cystatin C as a biomarker of chronic kidney disease: latest developments.

Authors:  Stefanie W Benoit; Eileen A Ciccia; Prasad Devarajan
Journal:  Expert Rev Mol Diagn       Date:  2020-05-25       Impact factor: 5.225

2.  Admission plasma uromodulin and the risk of acute kidney injury in hospitalized patients with cirrhosis: a pilot study.

Authors:  Kavish R Patidar; Pranav S Garimella; Etienne Macedo; James E Slaven; Marwan S Ghabril; Regina E Weber; Melissa Anderson; Eric S Orman; Lauren D Nephew; Archita P Desai; Naga P Chalasani; Tarek M El-Achkar
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2019-08-14       Impact factor: 4.052

Review 3.  Acute kidney injury: prediction, prognostication and optimisation for liver transplant.

Authors:  Nishita Jagarlamudi; Florence Wong
Journal:  Hepatol Int       Date:  2020-03-03       Impact factor: 6.047

Review 4.  Management of hepatorenal syndrome in liver cirrhosis: a recent update.

Authors:  Chinmay Bera; Florence Wong
Journal:  Therap Adv Gastroenterol       Date:  2022-06-14       Impact factor: 4.802

5.  'First week' is the crucial period for deciding living donor liver transplantation in patients with acute-on-chronic liver failure.

Authors:  Ashok Choudhury; Rajan Vijayaraghavan; Rakhi Maiwall; Manoj Kumar; Zhongping Duan; Chen Yu; Saeed Sadiq Hamid; Wasim Jafri; Amna Subhan Butt; Harshad Devarbhavi; Qin Ning; Ke Ma; Soek-Siam Tan; Akash Shukla; Radhakrishna Dhiman; Ajay Duseja; Sunil Taneja; C E Eapen; Ashish Goel; Sombat Treeprasertsuk; Mamun Al-Mahtab; Hasmik Ghazinyan; Dong Joon Kim; Manoj K Sahu; Guan Huei Lee; Laurentius A Lesmana; Rinaldi Cosmas Lesmana; Samir Shah; Zaigham Abbas; Jose D Sollano; P N Rao; Anand Kulkarni; Gamal Shiha; Ananta Shrestha; AKadir Dokmeci; Man Fung Yuen; Diana Alcantara Payawal; Kemal Fariz Kalista; V G Mohan Prasad; George K Lau; Fazal Karim; Priyanka Jain; Guresh Kumar; Vinod Arora; Viniyendra Pamecha; Piyush Sinha; Shiv K Sarin
Journal:  Hepatol Int       Date:  2021-10-04       Impact factor: 6.047

6.  Sarcopenia HIBA score predicts sarcopenia and mortality in patients on the liver transplant waiting list.

Authors:  Ezequiel Mauro; Juan Manuel Diaz; Lucrecia Garcia-Olveira; Juan Carlos Spina; Lorena Savluk; Fernanda Zalazar; Julia Saidman; Martin De Santibañes; Juan Pekolj; Eduardo De Santibañes; Gonzalo Crespo; Juan G Abraldes; Adrían Gadano
Journal:  Hepatol Commun       Date:  2022-03-03

7.  Development and Validation of Nomogram to Predict Acute Kidney Injury in Patients with Acute Myocardial Infarction Treated Invasively.

Authors:  Xuejun Zhou; Zhiqin Sun; Yi Zhuang; Jianguang Jiang; Nan Liu; Xuan Zang; Xin Chen; Haiyan Li; Haitao Cao; Ling Sun; Qingjie Wang
Journal:  Sci Rep       Date:  2018-06-27       Impact factor: 4.379

8.  Does Hepatic Impairment Influence Renal Function Parameters in Liver Cirrhosis?

Authors:  Tingxue Song; Zhe Jia; Xiaozhong Guo; Haitao Zhao; Wenchun Bao; Dan Han; Xinmiao Zhou; Xingshun Qi
Journal:  J Transl Int Med       Date:  2018-06-26

9.  Association Between the Concentration and Rangeability of Cystatin C and Mortality of COVID-19 Patients With or Without Type 2 Diabetes Mellitus: A Retrospective Analysis.

Authors:  Lei Yang; Dou Xu; Yiqing Tan; Bolin Li; Dan Zhu; Jingbo Wang; Hui Sun; Xinglong Liu; Xiaopu Zheng; Ling Zhu; Zhongyu Li
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-21       Impact factor: 5.555

Review 10.  Review of Serum Biomarkers and Models Derived from Them in HBV-Related Liver Diseases.

Authors:  JianPing Wu; WeiLin Mao
Journal:  Dis Markers       Date:  2020-07-21       Impact factor: 3.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.